

[Science Education Patient Care & Advocacy](#)
[Our Society](#) [Our Mission, Vision & Values](#) [EBMT Membership 2023](#) [Organisational Structure 2023](#) [Financial Highlights 2023](#) [EBMT Partners](#)

Breadcrumb

1. [Home](#)

Entity Print



Fabio Ciceri
ALWP Chair
Italy

Major achievements

The activity of the ALWP continues to increase thanks to the great contribution of the ALWP members and collaborators and the continuous efforts of the ALWP staff. Study proposals are presented with relevant questions for investigating factors associated with patients outcomes. All these achievements are possible with the continuous and voluntary work of distinguished colleagues, and I thank all of them

for it.

One of the main topics of the ALWP is the data collection on next-generation sequencing (NGS) data and use of novel drugs, with the aim to improve the quality of the registry and the scientific output of the publications to the benefit of the patient's care.

The number of transplants for patients with acute leukaemia is constantly growing, with increase in the HCT indications, as well the age of the patients and diseases. The role of age and donor kinship has been analysed in different transplant settings to implement the algorithm of donor selection for patients in need of HCT.

I am very grateful for your tireless efforts in sending such complex data, which will definitely lead to the generation of new knowledge to further advance the management of acute leukaemia.

Principal research studies

[COLLECTION OF NEXT-GENERATION SEQUENCING \(NGS\) DATA AND USE OF NOVEL DRUGS IN ACUTE LEUKEMIA PATIENTS](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Acute Lymphatic Leukaemia \(ALL\)](#)

[Acute Myeloid Leukaemia \(AML\)](#)

[Group](#)

[Acute Leukemia Working Party \(ALWP\)](#)

[Type of Stem Cell Treatment](#)

-

[Principal investigator](#)

[Prof M. Mohty](#)

[Frequency and Impact of Pre-Transplant Somatic Co-Occurring Mutations on Clinical Outcomes of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation: On Behalf of the EBMT Acute Leukemia Working Party](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Acute Myeloid Leukaemia \(AML\)](#)

Group

Acute Leukemia Working Party (ALWP)

Type of Stem Cell Treatment

Allogeneic

Principal investigator

Ali Bazarbachi

Long term outcomes and relative mortality in survivors of allogeneic hematopoietic cell transplantation in acute myeloid leukemia: an analysis from the ALWP of the

EBMT

Study type

Retrospective Studies

Diseases

Acute Myeloid Leukaemia (AML)

Group

Acute Leukemia Working Party (ALWP)

Type of Stem Cell Treatment

Allogeneic

Principal investigator

Vivek Patel

PTCY MMUD vs Haplo in active disease for AML

Study type

Retrospective Studies

Diseases

Acute Myeloid Leukaemia (AML)

Group

Acute Leukemia Working Party (ALWP)

Type of Stem Cell Treatment

Allogeneic - Haploidentical

Principal investigator

Frédéric Baron

Outcome after allogeneic SCT for MLL-PTD AML

Study type

Retrospective Studies

Diseases

Acute Myeloid Leukaemia (AML)

Group

Acute Leukemia Working Party (ALWP)

Type of Stem Cell Treatment

[Allogeneic](#)

[Principal investigator](#)

[Marta Pratcorona](#)

Key publications

[2023](#)

[Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Party of the EBMT](#)

[Group](#)

[Acute Leukemia Working Party \(ALWP\)](#)

[1st listed author](#)

[Ryszard Swoboda](#)

[Journal](#)

[Bone Marrow Transplant.](#)

[2023](#)

[Validation of the transplant conditioning intensity \(TCI\) index for allogeneic hematopoietic cell transplantation](#)

[Group](#)

[Acute Leukemia Working Party \(ALWP\)](#)

[1st listed author](#)

[Alexandros Spyridonidis](#)

[Journal](#)

[Bone Marrow Transplant.](#)

[2023](#)

[Comparison of fludarabine/melphalan \(FluMel\) with fludarabine/melphalan/BCNU or thiotepa \(FBM/FTM\) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party](#)

[Group](#)

[Acute Leukemia Working Party \(ALWP\)](#)

[1st listed author](#)

[Jesús Duque-Afonso](#)

[Journal](#)

[Bone Marrow Transplant.](#)

[2023](#)

[Thiotepa-based regimens are a valid alternative to total body irradiation-based reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia: a retrospective study on behalf of the Acute Leukemia Working Party of the EBMT](#)

[Group](#)

[Acute Leukemia Working Party \(ALWP\)](#)

[1st listed author](#)

[Giorgia Battipaglia](#)

[Journal](#)

[Transplant Cell Ther.](#)

[2023](#)

[The role of anti-thymocyte globulin in allogeneic stem cell transplantation \(HSCT\) from HLA-matched unrelated donors \(MUD\) for secondary AML in remission: a study from the ALWP /EBMT](#)

[Group](#)

[Acute Leukemia Working Party \(ALWP\)](#)

[1st listed author](#)

[Arnon Nagler](#)


[Journal](#)

[Bone Marrow Transplant.](#)

[See the full list of the ALWP 2023 publications](#)



Impact factor (Acute Leukaemia)



2021 2022 2023

Oral presentations	10	14	23
Poster presentations	8	22	22
Educational events	1	4	3



[Event](#)

49th Annual Meeting of the EBMT

Apr 23, 2023 - Apr 26, 2023 / Paris, France

Discover more

- 7th IPC Symposium Advances in Transplant and Cellular Immunotherapy in Older Patients - 23-25 June 2023 in Marseille, France

VISIT THE ALWP WEBPAGE